Literature DB >> 27104648

Comparison of serum biomarkers between patients with asthma and with chronic obstructive pulmonary disease.

Seon-Sook Han1,2, Won Ho Lee1, Yoonki Hong1,2, Woo Jin Kim1,2, JeongHee Yang3, Myoung Nam Lim4, Seung-Joon Lee1,2, Jae-Woo Kwon1,2,5.   

Abstract

OBJECTIVE: Asthma and chronic obstructive pulmonary disease (COPD) have distinct pathophysiological mechanisms but sometimes share similar clinical manifestations. Distinguishing between these diseases is important. This study compared the profiles of serum biomarkers between patients with asthma and those with COPD.
METHODS: Serum levels of the chitinase like protein YKL-40, periostin, interleukin (IL)-18, and chemokine (C--C motif) ligand 18 (CCL18) were measured in asthma patients (n = 20), COPD patients (n = 16), and normal controls (n = 20).
RESULTS: Serum levels of YKL-40 were higher in COPD patients [median (range), 55 (17-565) versus 208 (74-922) ng/mL, p < 0.0001], but no differences were observed between asthma and COPD patients after adjusting for age and forced expiratory volume in 1 s (FEV1). No differences in serum levels of periostin, IL-18, or CCL18 were observed between the patient groups. Total IgE and airway hypersensitivity were negatively correlated (r = -0.485, p = 0.007). CCL18 levels were related to patients' age in asthmatic patients (r = -0.562, p = 0.010). Serum levels of CCL18 and IL-18 were positively correlated in patients with COPD (r = 0.696, p = 0.003).
CONCLUSIONS: No differences in the serum profiles of periostin, IL-18, or CCL18 were observed between patients with asthma and those with COPD. Serum levels of YKL-40 were not different between asthma and COPD patients after adjusting for age and FEV1. There were negative correlation between CCL18 and age in patients with asthma and positive correlation between IL-18 and CCL18 in patients with COPD.

Entities:  

Keywords:  Asthma; CCL18; COPD; IL-18; YKL-40; periostin

Mesh:

Substances:

Year:  2016        PMID: 27104648     DOI: 10.3109/02770903.2015.1056347

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  6 in total

Review 1.  Association between YKL-40 and asthma: a systematic meta-analysis.

Authors:  Yihan Jin; Jie Song; Fang Xu; Di Zhang; Jinfang He; Jiakun Zheng; Yanan Zhang; Jintong Li; Yikun Guo; Mengjiao Xu; Xiangfeng Yu; Yanbin Liu; Qinghua Liu; Jun Yan
Journal:  Sleep Breath       Date:  2021-10-16       Impact factor: 2.655

2.  Association between the length of the MUC8-minisatellite 5 region and susceptibility to chronic obstructive pulmonary disease (COPD).

Authors:  Se-Ra Lee; Won-Tae Kim; Tae Nam Kim; Jong Kil Nam; Woo Jin Kim; Sun-Hee Leem
Journal:  Genes Genomics       Date:  2017-11-09       Impact factor: 1.839

Review 3.  The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review.

Authors:  Xiang Tong; Dongguang Wang; Sitong Liu; Yao Ma; Zhenzhen Li; Panwen Tian; Hong Fan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-01-30

4.  Serum periostin does not reflect type 2-driven inflammation in COPD.

Authors:  O A Carpaij; F O W Muntinghe; M B Wagenaar; J W Habing; W Timens; H A M Kerstjens; M C Nawijn; L I Z Kunz; P S Hiemstra; G W Tew; C T J Holweg; C A Brandsma; M van den Berge
Journal:  Respir Res       Date:  2018-06-07

5.  Overexpression of chitotriosidase and YKL-40 in peripheral blood and sputum of healthy smokers and patients with chronic obstructive pulmonary disease.

Authors:  Sebastian Majewski; Damian Tworek; Karolina Szewczyk; Justyna Kiszałkiewicz; Zofia Kurmanowska; Ewa Brzeziańska-Lasota; Hanna Jerczyńska; Adam Antczak; Wojciech Jerzy Piotrowski; Paweł Górski
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-07-22

6.  Plasma YKL-40 and NGAL are useful in distinguishing ACO from asthma and COPD.

Authors:  Jing Wang; Huajie Lv; Zhuang Luo; Shan Mou; Jing Liu; Chang Liu; Shiying Deng; Youfan Jiang; Jiachen Lin; Chengzhou Wu; Xianhong Liu; Jinzhi He; Depeng Jiang
Journal:  Respir Res       Date:  2018-03-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.